Google Life Sciences Group To Wage War On Diabetes


 
2.6k
Shares
 

By Fred O'Connor

Google may still be working on a name for its recently spun off life sciences group, but the division already has a foe: diabetes.

On Monday, Google said the chronic disease will be the first illness the life sciences division focuses on as it becomes a separate business under the new Alphabet holding company.

The search giant also wants to digitize how people manage their diabetes and is partnering with drug maker Sanofi to develop technologies that could aid in that process.

Diabetics use mobile apps, medical devices and even pieces of paper to record food intake, log blood sugar levels, track fitness activities and determine medication doses, Google said. Given the hassles of using these unintegrated methods, only around half of diabetics achieve their target glucose levels.

The medical consequences of not managing diabetes include heart disease, stroke and nerve damage.

Since the partnership is new, neither Google nor Sanofi could say exactly how the search giant's technology could be used by the pharmaceutical company. The goal, though, is to use Google technology including sensors, wearable devices and analytics tools to give doctors and patients more insight into how to better manage diabetes.

For example, the technology could help explain to a physician why a person's glucose level has spiked for several days or provide real-time information related to a patient's insulin dosage or diet.

Google Life Sciences chief Andy Conrad stated smart insulin and measurement devices could come out of the partnership.

The deal's financial terms weren't disclosed.

Google's life sciences group has made other forays into diabetes research. The company is working with drug company Novartis on creating a contact lens that uses tears to measure a person's blood sugar levels. Earlier this month, Google and medical device maker Dexcom said they would collaborate on creating a small sensor that would continuously monitor a person's glucose levels and be connected to the cloud.

Once part of the secretive Google X research lab, the life sciences unit became its own company under a massive reorganization at the search giant. A name hasn't been selected for the new venture.


 
2.6k
Shares
 

Articles in this issue:

Journal of Medicine Sign Up

Get the Journal of Medicine delivered to your inbox.

Thank you for subscribing.

No membership required*

Masthead

    • Editor-in Chief:
    • Theodore Massey
    • Editor:
    • Robert Sokonow
    • Editorial Staff:
    • Musaba Dekau
      Lin Takahashi
      Thomas Levine
      Cynthia Casteneda Avina
      Ronald Harvinger
      Lisa Andonis

Leave a Comment

Please keep in mind that all comments are moderated. Please do not use a spam keyword or a domain as your name, or else it will be deleted. Let's have a personal and meaningful conversation instead. Thanks for your comments!

*This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.